Literature DB >> 18972208

The effect of iNOS inhibitors and hyperbaric oxygen treatment in a rat model of experimental colitis.

Cemal Nuri Ercin1, Zeki Yesilova, Ahmet Korkmaz, Ayhan Ozcan, Cagatay Oktenli, Ahmet Uygun.   

Abstract

AIM: Our aim was to investigate the effectiveness of aminoguanidine (AMG), an inducible nitric oxide synthase inhibitor, and hyperbaric oxygen (HBO) treatment in an experimental colitis model.
METHODS: We induced colitis in rats. In the control group, we applied 2 ml serum physiologic intraperitoneally for 7 days. In the HBO group, 100% oxygen at 2.4 atm pressure was applied for 7 days. In the AMG group, 100 mg/kg AMG was applied intraperitoneally for 7 days. In the HBO + AMG group, HBO and AMG were applied, respectively. At the end of 7 days, rats were sacrificed and the distal 10 cm part of colon was examined macro- and microscopically.
RESULTS: Severity of colitis and NO activities were reduced by AMG, HBO, and HBO + AMG application. There was histologically significant improvement, especially in the HBO + AMG group.
CONCLUSIONS: Both HBO and AMG were significantly effective in preventing weight loss, reducing NO activities, and severity of colitis, when comparing HBO and AMG separately.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18972208     DOI: 10.1007/s10620-008-0498-1

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  43 in total

Review 1.  Nitric oxide in inflammatory bowel disease.

Authors:  Raymond K Cross; Keith T Wilson
Journal:  Inflamm Bowel Dis       Date:  2003-05       Impact factor: 5.325

2.  Direct determination of colonic nitric oxide level--a sensitive marker of disease activity in ulcerative colitis.

Authors:  D Rachmilewitz; R Eliakim; Z Ackerman; F Karmeli
Journal:  Am J Gastroenterol       Date:  1998-03       Impact factor: 10.864

3.  Suppression of pro-inflammatory cytokine release by selective inhibition of inducible nitric oxide synthase in mucosal explants from patients with ulcerative colitis.

Authors:  E Kankuri; M Hämäläinen; M Hukkanen; P Salmenperä; E Kivilaakso; H Vapaatalo; E Moilanen
Journal:  Scand J Gastroenterol       Date:  2003-02       Impact factor: 2.423

4.  Laryngeal radionecrosis and hyperbaric oxygen therapy: report of 18 cases and review of the literature.

Authors:  G A Filntisis; R E Moon; K L Kraft; J C Farmer; R L Scher; C A Piantadosi
Journal:  Ann Otol Rhinol Laryngol       Date:  2000-06       Impact factor: 1.547

5.  Expression of nitric oxide synthases and effects of L-arginine and L-NMMA on nitric oxide production and fluid transport in collagenous colitis.

Authors:  A Perner; L Andresen; M Normark; B Fischer-Hansen; S Sørensen; J Eugen-Olsen; J Rask-Madsen
Journal:  Gut       Date:  2001-09       Impact factor: 23.059

Review 6.  Role of reactive metabolites of oxygen and nitrogen in inflammatory bowel disease.

Authors:  Kevin P Pavlick; F Stephen Laroux; John Fuseler; Robert E Wolf; Laura Gray; Jason Hoffman; Matthew B Grisham
Journal:  Free Radic Biol Med       Date:  2002-08-01       Impact factor: 7.376

7.  Enhanced colonic nitric oxide generation and nitric oxide synthase activity in ulcerative colitis and Crohn's disease.

Authors:  D Rachmilewitz; J S Stamler; D Bachwich; F Karmeli; Z Ackerman; D K Podolsky
Journal:  Gut       Date:  1995-05       Impact factor: 23.059

8.  The effect of nitric oxide synthases inhibitors on inflammatory bowel disease in a rat model.

Authors:  Charalambos J Pilichos; Ilias A Kouerinis; George C Zografos; Dimiris P Korkolis; Athena A Preza; Maria Gazouli; Evangelos I Menenakos; Antonios E Loutsidis; Flora Zagouri; Vassilis G Gorgoulis; Constantin I Fotiadis
Journal:  In Vivo       Date:  2004 Jul-Aug       Impact factor: 2.155

9.  Hyperbaric oxygenation in severe perineal Crohn's disease.

Authors:  J F Colombel; D Mathieu; J M Bouault; X Lesage; P Zavadil; P Quandalle; A Cortot
Journal:  Dis Colon Rectum       Date:  1995-06       Impact factor: 4.585

10.  Effects of nitric oxide synthase inhibition on the pathophysiology observed in a model of chronic granulomatous colitis.

Authors:  M B Grisham; R D Specian; T E Zimmerman
Journal:  J Pharmacol Exp Ther       Date:  1994-11       Impact factor: 4.030

View more
  7 in total

1.  Effects of hyperoxia exposure on metabolic markers and gene expression in 3T3-L1 adipocytes.

Authors:  P Quintero; P González-Muniesa; D F García-Díaz; J A Martínez
Journal:  J Physiol Biochem       Date:  2012-04-26       Impact factor: 4.158

2.  The role of hyperbaric oxygen therapy in the treatment of radiation lesions.

Authors:  Clara Gaio-Lima; João Castedo; Mafalda Cruz; Margarida Candeias; Óscar Camacho
Journal:  Clin Transl Oncol       Date:  2022-08-17       Impact factor: 3.340

3.  Hyperbaric oxygen treatment for inflammatory bowel disease: a systematic review and analysis.

Authors:  Daniel A Rossignol
Journal:  Med Gas Res       Date:  2012-03-15

4.  Hyperbaric oxygen therapy ameliorates TNBS-induced acute distal colitis in rats.

Authors:  Rogério S Parra; Alexandre H Lopes; Eleonora U Carreira; Marley R Feitosa; Fernando Q Cunha; Sérgio B Garcia; Thiago M Cunha; José J R da Rocha; Omar Féres
Journal:  Med Gas Res       Date:  2015-04-16

Review 5.  Hyperbaric oxygen therapy as a potential treatment for post-traumatic stress disorder associated with traumatic brain injury.

Authors:  David J Eve; Martin R Steele; Paul R Sanberg; Cesar V Borlongan
Journal:  Neuropsychiatr Dis Treat       Date:  2016-10-20       Impact factor: 2.570

6.  Ethanol Extract of Antrodia camphorata Grown on Germinated Brown Rice Suppresses Inflammatory Responses in Mice with Acute DSS-Induced Colitis.

Authors:  Dong Ki Park; Hye-Jin Park
Journal:  Evid Based Complement Alternat Med       Date:  2013-05-30       Impact factor: 2.629

7.  iNOS expression and osteocyte apoptosis in idiopathic, non-traumatic osteonecrosis.

Authors:  Jun Wang; Ali Kalhor; Shifeier Lu; Ross Crawford; Jiang-Dong Ni; Yin Xiao
Journal:  Acta Orthop       Date:  2014-09-05       Impact factor: 3.717

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.